Related Experiment Video
Updated: Jul 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study
Jean-Jacques Parienti1, Veronique Massari, David Rey
1Epidemiologie, Systemes d'Informations, Modelisation, Institut National de la Sante et de la Recherche Medicale U707, Paris, France. parienti-jj@chu-caen.fr
Abstract:
Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antiviral Nucleoside Inhibitors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retroviruses
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Retrovirus Life Cycles

